GHRP-2 Dosage: What Community Protocols Report
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← GHRP-2 encyclopedia entry · See also: GHRP-6 dosage · Ipamorelin dosage
GHRP-2 (pralmorelin) is approved in Japan as a diagnostic agent for growth-hormone secretion testing — but it is not FDA-approved for therapeutic use, and the community use as a GH-boosting peptide is investigational. The figures below reflect community practice, documented for education, not instructions for use.
The short version
GHRP-2 is a growth-hormone-releasing peptide — a ghrelin-receptor agonist that triggers a GH pulse. It sits in the same family as ipamorelin and GHRP-6, and its only formal approval anywhere is as a diagnostic (pralmorelin, in Japan) used to test the pituitary's ability to release growth hormone. That diagnostic approval is sometimes misread as a therapeutic green light; it is not.
What community protocols report
| Parameter | Commonly reported |
|---|---|
| Amount | ~100–300 mcg per dose |
| Frequency | 1–3× daily |
| Timing | Pre-bed and/or post-workout |
| Route | Subcutaneous |
As with the other GH secretagogues, the timing tracks the body's own GH rhythm, and GHRP-2 is frequently combined with a GHRH analog like CJC-1295 on the complementary-mechanism theory. These conventions come from community use, not approval-grade therapeutic trials.
GHRP-2 is more potent at releasing GH than ipamorelin, but it also raises cortisol, prolactin, and appetite more. Ipamorelin is the "clean," selective option with little of that off-target effect. GHRP-6 is the strongest appetite stimulant of the three. The trade-off is potency versus selectivity — which is the main reason people choose one over another. See the ipamorelin and GHRP-6 dosage pages.
Reconstitution basics
GHRP-2 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before microgram doses can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact draw; it cannot verify the contents of an unregulated vial.
Frequently asked questions
Does the Japanese diagnostic approval make it safe to use as a therapy?
No. A diagnostic approval covers a single, controlled test dose for assessment — it is not the same as approval for repeated therapeutic use, and it does not apply in the US.
Why combine it with CJC-1295?
The GHRH analog raises the baseline GH drive while GHRP-2 triggers a pulse; the pairing is a community convention, not a validated combination.
Will it stimulate appetite?
Yes, more than ipamorelin — appetite stimulation is one of the off-target effects that distinguishes the older GHRPs from the selective ones.
Sources
- Bowers CY. Growth hormone-releasing peptides — pharmacology and the GHRP class.
- Pralmorelin (GHRP-2) diagnostic approval, Japan (growth-hormone stimulation testing).
Medical disclaimer: Education only, not medical advice. GHRP-2 is not FDA approved for therapeutic use. Dosing figures reflect community practice, not a recommendation. Do not self-administer; consult a licensed clinician.